- Home
- IBG vs SBFM Comparison
IBG vs SBFM Comparison
Compare IBG & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBG
- SBFM
- Stock Information
- Founded
- IBG 2018
- SBFM 2006
- Country
- IBG Australia
- SBFM United States
- Employees
- IBG N/A
- SBFM N/A
- Industry
- IBG Beverages (Production/Distribution)
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- IBG Consumer Staples
- SBFM Health Care
- Exchange
- IBG Nasdaq
- SBFM Nasdaq
- Market Cap
- IBG 5.4M
- SBFM 6.5M
- IPO Year
- IBG 2024
- SBFM N/A
- Fundamental
- Price
- IBG $0.57
- SBFM $1.40
- Analyst Decision
- IBG Strong Buy
- SBFM Strong Buy
- Analyst Count
- IBG 1
- SBFM 1
- Target Price
- IBG N/A
- SBFM $15.00
- AVG Volume (30 Days)
- IBG 529.3K
- SBFM 41.6K
- Earning Date
- IBG 08-26-2025
- SBFM 08-12-2025
- Dividend Yield
- IBG N/A
- SBFM N/A
- EPS Growth
- IBG N/A
- SBFM N/A
- EPS
- IBG N/A
- SBFM N/A
- Revenue
- IBG $2,931,243.00
- SBFM $36,341,741.00
- Revenue This Year
- IBG N/A
- SBFM $32.20
- Revenue Next Year
- IBG N/A
- SBFM $32.74
- P/E Ratio
- IBG N/A
- SBFM N/A
- Revenue Growth
- IBG N/A
- SBFM 19.22
- 52 Week Low
- IBG $0.44
- SBFM $1.17
- 52 Week High
- IBG $3.35
- SBFM $3.90
- Technical
- Relative Strength Index (RSI)
- IBG 41.82
- SBFM 41.45
- Support Level
- IBG $0.54
- SBFM $1.36
- Resistance Level
- IBG $0.72
- SBFM $1.52
- Average True Range (ATR)
- IBG 0.07
- SBFM 0.07
- MACD
- IBG -0.01
- SBFM -0.00
- Stochastic Oscillator
- IBG 10.71
- SBFM 25.00
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.